Company profile for Intas Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown ...
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
India
Address
Address
Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad, Gujarat
Telephone
Telephone
+91 79 6652 3100
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI North America

Not Confirmed

envelop Contact Supplier

CPhI North America

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
“Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”
This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

Impressions: 957

https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

Radio Compass
12 Mar 2025

VLOG #PharmaReel

[Sponsored by another company]

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels
In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  

Impressions: 2197

https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

#PharmaFlow by PHARMACOMPASS
24 Apr 2025

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/accord-biopharma-inc-announces-completion-of-udenyca-pegfilgrastim-cbqv-franchise-acquisition-from-coherus-biosciences-inc-expanding-us-biosimilar-portfolio-302427584.html

PR NEWSWIRE
14 Apr 2025

https://www.globenewswire.com/news-release/2025/04/14/3060846/33333/en/Coherus-Completes-Strategic-Transformation-with-Successful-Divestiture-of-UDENYCA-Franchise.html

GLOBENEWSWIRE
14 Apr 2025

https://www.prnewswire.com/news-releases/bio-thera-solutions-announces-exclusive-commercialization-and-license-agreement-with-intas-pharmaceuticals-for-bat2506-a-proposed-biosimilar-referencing-simponi-golimumab-in-the-united-states-of-america-302372271.html

PR NEWSWIRE
10 Feb 2025

https://www.prnewswire.com/news-releases/accord-biopharma-inc-recognizes-milestone-as-more-than-10-000-patients-gain-access-to-camcevi-leuprolide-302352332.html

PR NEWSWIRE
16 Jan 2025

https://investors.coherus.com/news-releases/news-release-details/coherus-announces-agreement-divest-udenycar-franchise-558

PRESS RELEASE
04 Dec 2024

https://www.globenewswire.com/news-release/2024/12/03/2990450/33333/en/Coherus-Announces-Agreement-to-Divest-UDENYCA-Franchise-for-up-to-558-million-to-Intas-Pharmaceuticals-Ltd.html

GLOBENEWSWIRE
03 Dec 2024

01

Doxorubicin Hydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Doxorubicin Hydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS arrow-down JDMF EU-WCInactive-api NDC KDMF arrow-down VMF Others AUDIT
blank

02

Pregabalin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Pregabalin

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WCInactive-api NDC KDMF VMF Others AUDIT
blank

03

Rivaroxaban

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Rivaroxaban

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WCInactive-api NDC KDMF VMF Others AUDIT
blank

04

Capecitabine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Capecitabine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Capecitabine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Capecitabine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Carmustine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Carmustine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Docetaxel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Docetaxel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Fingolimod Hydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Fingolimod Hydrochloride

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Gemcitabine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Gemcitabine

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Paclitaxel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Iran Expo
Not Confirmed
arrow

Paclitaxel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Iran Expo
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

LISTED APIs

read-more
read-more
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of ...
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year.
blank

01

Iran Expo
Not Confirmed
arrow
arrow
Iran Expo
Not Confirmed

Intas Pharmaceuticals

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year.

About the Company : Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal ne...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Imuldosa (ustekinumab) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23. It is indicated for the treatment of moderate to severe plague psoriasis.


Lead Product(s): Ustekinumab

Therapeutic Area: Dermatology Brand Name: Imuldosa

Study Phase: Approved FDFProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 19, 2024

blank

01

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : Imuldosa (ustekinumab) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23. It is indicated for the treatment of moderate to severe plague psoriasis.

Product Name : Imuldosa

Product Type : Antibody

Upfront Cash : Inapplicable

October 19, 2024

blank

Details:

Tecfidera-Generic (dimethyl fumarate) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with relapsing forms of multiple sclerosis.


Lead Product(s): Dimethyl Fumarate

Therapeutic Area: Neurology Brand Name: Tecfidera-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 19, 2023

blank

02

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : Tecfidera-Generic (dimethyl fumarate) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with relapsing forms of multiple sclerosis.

Product Name : Tecfidera-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 19, 2023

blank

Details:

The agreement aims for the commercialisation of HIPRA's mRNA COVID-19 vaccine, Bimervax, which combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, in the United Kingdom.


Lead Product(s): COVID-19 Vaccine Recombinant, Adjuvanted

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Approved FDFProduct Type: Vaccine

Sponsor: Laboratorios HIPRA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 08, 2023

blank

03

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Lead Product(s) : COVID-19 Vaccine Recombinant, Adjuvanted

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Laboratorios HIPRA

Deal Size : Undisclosed

Deal Type : Agreement

Details : The agreement aims for the commercialisation of HIPRA's mRNA COVID-19 vaccine, Bimervax, which combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, in the United Kingdom.

Product Name : Undisclosed

Product Type : Vaccine

Upfront Cash : Undisclosed

April 08, 2023

blank

Details:

Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. It is indicated for the treatment of relapsing forms of multiple sclerosis.


Lead Product(s): Teriflunomide

Therapeutic Area: Neurology Brand Name: Aubagio-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 13, 2023

blank

04

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. It is indicated for the treatment of relapsing forms of multiple sclerosis...

Product Name : Aubagio-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 13, 2023

blank

Details:

Lurasidone hydrochloride is a, oral atypical antipsychotic, full antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors, it is a first-line treatment option for the management of schizophrenia in adults and adolescents.


Lead Product(s): Lurasidone Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Lurasidone-Generic

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 21, 2023

blank

05

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : Lurasidone hydrochloride is a, oral atypical antipsychotic, full antagonist at dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors, it is a first-line treatment option for the management of schizophrenia in adults and adolescents.

Product Name : Lurasidone-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 21, 2023

blank

Details:

Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.


Lead Product(s): Plerixafor

Therapeutic Area: Oncology Brand Name: Mozobil-Generic

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 11, 2022

blank

06

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.

Product Name : Mozobil-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 11, 2022

blank

Details:

Carmustine is an anti-cancer ("antineoplastic") chemotherapy drug classified as an alkylating agent. It works by helping to halt the growth of cancer cells (cancer cell division).


Lead Product(s): Carmustine

Therapeutic Area: Oncology Brand Name: Carmustine-Generic

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 23, 2022

blank

07

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : Carmustine is an anti-cancer ("antineoplastic") chemotherapy drug classified as an alkylating agent. It works by helping to halt the growth of cancer cells (cancer cell division).

Product Name : Carmustine-Generic

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

August 23, 2022

blank

Details:

Through this partnership with Foresee on the launch of CAMCEVI, Accord BioPharma with razor sharp focus on specialty pharmaceuticals, which will go beyond biology to bring more access to high-quality medicines to patients across the U.S.


Lead Product(s): Leuprolide Mesylate

Therapeutic Area: Oncology Brand Name: Camcevi

Study Phase: Approved FDFProduct Type: Hormone

Sponsor: Foresee Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership April 04, 2022

blank

08

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : Through this partnership with Foresee on the launch of CAMCEVI, Accord BioPharma with razor sharp focus on specialty pharmaceuticals, which will go beyond biology to bring more access to high-quality medicines to patients across the U.S.

Product Name : Camcevi

Product Type : Hormone

Upfront Cash : Undisclosed

April 04, 2022

blank

Details:

CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on Day 0 and Week 24.


Lead Product(s): Leuprolide Mesylate

Therapeutic Area: Oncology Brand Name: Camcevi

Study Phase: Approved FDFProduct Type: Hormone

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 31, 2022

blank

09

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on D...

Product Name : Camcevi

Product Type : Hormone

Upfront Cash : Inapplicable

March 31, 2022

blank

Details:

Sondelbay (teriparatide), is a self-administered, once-a-day subcutaneous injection for patients with osteoporosis using a pen device, is indicated for treatment of osteoporosis.


Lead Product(s): Teriparatide

Therapeutic Area: Musculoskeletal Brand Name: Sondelbay

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 28, 2022

blank

10

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Accord healthcare

United Kingdom
arrow
Iran Expo
Not Confirmed

Details : Sondelbay (teriparatide), is a self-administered, once-a-day subcutaneous injection for patients with osteoporosis using a pen device, is indicated for treatment of osteoporosis.

Product Name : Sondelbay

Product Type : Peptide

Upfront Cash : Inapplicable

January 28, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Excipients

Click here to find the perfect excipient manufacturers by their capabilities

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Intas Pharmaceuticals and get a quotation

Intas Pharmaceuticals is a supplier offers 48 products (APIs, Excipients or Intermediates).

Find a price of Doxorubicin Hydrochloride bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Pregabalin bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Rivaroxaban bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Capecitabine bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Carmustine bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Docetaxel bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Fingolimod Hydrochloride bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Gemcitabine bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Paclitaxel bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Teriflunomide bulk with DMF, CEP offered by Intas Pharmaceuticals

Find a price of Azacitidine bulk with DMF offered by Intas Pharmaceuticals

Find a price of Docetaxel bulk with CEP offered by Intas Pharmaceuticals

Find a price of Imatinib Mesylate bulk with CEP offered by Intas Pharmaceuticals

Find a price of Bendamustine Hydrochloride bulk with DMF offered by Intas Pharmaceuticals

Find a price of Cabazitaxel bulk with DMF offered by Intas Pharmaceuticals

Find a price of Carfilzomib bulk with DMF offered by Intas Pharmaceuticals

Find a price of Dasatinib bulk with DMF offered by Intas Pharmaceuticals

Find a price of Decitabine bulk with DMF offered by Intas Pharmaceuticals

Find a price of Dimethyl Fumarate bulk with DMF offered by Intas Pharmaceuticals

Find a price of Diroximel fumarate bulk with DMF offered by Intas Pharmaceuticals

Find a price of Dofetilide bulk with DMF offered by Intas Pharmaceuticals

Find a price of Erlotinib Hydrochloride bulk with DMF offered by Intas Pharmaceuticals

Find a price of Fampridine bulk with DMF offered by Intas Pharmaceuticals

Find a price of Fesoterodine bulk with DMF offered by Intas Pharmaceuticals

Find a price of Lacosamide bulk with DMF offered by Intas Pharmaceuticals

Find a price of Lurasidone Hydrochloride bulk with DMF offered by Intas Pharmaceuticals

Find a price of Perampanel bulk with DMF offered by Intas Pharmaceuticals

Find a price of Prasugrel Hydrochloride bulk with DMF offered by Intas Pharmaceuticals

Find a price of Ribociclib bulk with DMF offered by Intas Pharmaceuticals

Find a price of Ruxolitinib Phosphate bulk with DMF offered by Intas Pharmaceuticals

Find a price of Sodium Thiosulfate bulk with DMF offered by Intas Pharmaceuticals

Find a price of Ticagrelor bulk with CEP offered by Intas Pharmaceuticals

Find a price of Tipiracil Hydrochloride bulk with DMF offered by Intas Pharmaceuticals

Find a price of Tofacitinib Citrate bulk with DMF offered by Intas Pharmaceuticals

Find a price of Trazodone Hydrochloride bulk with DMF offered by Intas Pharmaceuticals

Find a price of Trifluridine bulk with DMF offered by Intas Pharmaceuticals

Find a price of Vilazodone Hydrochloride bulk with DMF offered by Intas Pharmaceuticals

Find a price of Trazodone hydrochloride, Milled, Unmilled bulk with CEP offered by Intas Pharmaceuticals

Find a price of Lacosamide, Form I, milled bulk with CEP offered by Intas Pharmaceuticals

Find a price of Apremilast bulk offered by Intas Pharmaceuticals

Find a price of Azacitidine bulk offered by Intas Pharmaceuticals

Find a price of Dabigatran Etexilate Mesylate bulk offered by Intas Pharmaceuticals

Find a price of Docetaxel bulk offered by Intas Pharmaceuticals

Find a price of Epirubicin Hydrochloride bulk offered by Intas Pharmaceuticals

Find a price of Pazopanib Hydrochloride bulk offered by Intas Pharmaceuticals

Find a price of Relugolix bulk offered by Intas Pharmaceuticals

Find a price of Doxorubicin Hydrochloride bulk offered by Intas Pharmaceuticals

Find a price of Sodium Methoxide Solution bulk offered by Intas Pharmaceuticals

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty